沃爾特和伊萊紮霍爾醫學研究所的

2023年7月5日

周三,05年7月,2023年,醫學研究未來基金(MRFF)投資975萬美元建立MedChem澳大利亞,一個新的國家藥物化學項目,將整合三大醫學化學組從悉尼大學,莫納什大學和沃爾特和伊萊紮霍爾醫學研究所(WEHI)。這三個機構,與澳大利亞治療創新(TIA)合作,將共同指導早期項目的過程確定候選藥物潛在的商業價值。除了MRFF國家關鍵研究的基礎設施投資格蘭特,合作夥伴將合計超過500萬美元建立MedChem澳大利亞,將項目的種子資金總額約1500萬美元在未來五年。這將是總部在莫納什醫藥科學研究所(MIPS)。MedChem澳大利亞將幫助填補一個重要能力差距在藥物發現管道。這種差距之間存在基本藥物發現生物學計劃和定義的生成和優化候選藥物分子有可能吸引所需的商業夥伴關係正式的臨床開發項目的支持。“從承諾創建分子藥物研究“點擊率”是一個巨大的挑戰,仍然是一個主要差距在澳大利亞藥物發現工作;MedChem澳大利亞將填補這一空缺,”Michael Kassiou教授說藥物發現的學術主任倡議在悉尼大學化學學院,誰將領導MedChem澳大利亞的悉尼節點。“藥物發現項目在悉尼大學的興奮與蒙納士學院合作醫藥科學和WEHI創建這個國家急需的框架。這將提高我們的翻譯能力至關重要的發現和燃料生物生態係統在澳大利亞。” Serving as co-lead of MedChem Australia is Professor Paul Stupple, Director of the Australian Translational Medicinal Chemistry Facility (ATMCF) within MIPS. He said that although Australia has an enviable reputation in fundamental biology, the nation’s record in translating discoveries into commercially attractive drug candidates needs to improve. “Ultimately, the primary goal of MedChem Australia is to fill a critical capability gap to put Australia at the forefront of drug candidate translation and strengthen sovereign outcomes when it comes to the development of home-grown, high-quality medicines,” he said. “MedChem Australia will deliver preclinical candidates, increasing opportunities for new biomed spinouts, and engage actively with industry to drive investment and generate new jobs.” Professor Guillaume Lessene, Theme Leader of New Medicines and Advanced Technologies at WEHI, will lead the WEHI node of MedChem Australia. He said, “This initiative will accelerate our collaborative efforts to turn the latest scientific discoveries into new treatments and therapies. “While the National Drug Discovery Centre (NDDC), headquartered at WEHI, addresses the early challenges in drug discovery, we have been missing the next crucial steps. Together, MedChem Australia and the NDDC are establishing the foundation of a powerful pipeline of translation from discovery to new medicines.” Also co-leading the project from MIPS is Professor Susan Charman, Director of the Centre for Drug Candidate Optimisation (CDCO), a collaborative research centre that provides expertise and infrastructure to multidisciplinary drug discovery teams. “MedChem Australia will address gaps within Australia’s current drug discovery environment by integrating the expertise of three of the country’s leading medicinal chemistry groups with our expertise in biopharmaceutical properties and pharmacokinetic characterisation to deliver high-quality preclinical drug candidates,” Charman said. “With this significant investment from the MRFF, combined with the backing of TIA, this national consortium will transform drug discovery in Australia.” Image credit: iStock.com/BsWei